Yusaku Iwasaki

Prof. Yusaku Iwasaki

Kyoto Prefectural University, Kyōto, Japan
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
CGChayon Goswami
Chayon Goswami
YIYusaku Iwasaki
Yusaku Iwasaki
TYToshihiko Yada
Toshihiko Yada

1 November 2019 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YIYusaku Iwasaki
Yusaku Iwasaki
PKParmila Kumari
Parmila Kumari
LWLei Wang
Lei Wang
SHShizu Hidema
Shizu Hidema
KNKatsuhiko Nishimori
Katsuhiko Nishimori
TYToshihiko Yada
Toshihiko Yada

16 June 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
UNUtano Nakamura
Utano Nakamura
TNTaichi Nohmi
Taichi Nohmi
RSRiho Sagane
Riho Sagane
JHJun Hai
Jun Hai
KOKento Ohbayashi
Kento Ohbayashi
YIYusaku Iwasaki
Yusaku Iwasaki
Gamma-aminobutyric acid (GABA) is present in the mammalian brain as the main inhibitory neurotransmitter and in foods. It is widely used as a supplement that regulates brain function through stress-reducing and sleep-enhancing effects. However, its underlying mechanisms remain poorly understood, as it is reportedly unable to cross the blood–brain barrier. Here, we explored whether a single peroral administration of GABA affects feeding behavior as an evaluation of brain function and the involvement of vagal afferent nerves. Peroral GABA at 20 and 200 mg/kg immediately before refeeding suppressed short-term food intake without aversive behaviors in mice. However, GABA administration 30 min before refeeding demonstrated no effects. A rise in circulating GABA concentrations by the peroral administration of 200 mg/kg GABA was similar to that by the intraperitoneal injection of 20 mg/kg GABA, which did not alter feeding. The feeding suppression by peroral GABA was blunted by the denervation of vagal afferents. Unexpectedly, peroral GABA alone did not alter vagal afferent activities histologically. The coadministration of a liquid diet and GABA potentiated the postprandial activation of vagal afferents, thereby enhancing postprandial satiation. In conclusion, dietary GABA activates vagal afferents in collaboration with meals or meal-evoked factors and regulates brain function including feeding behavior.

8 June 2021 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
KOKento Ohbayashi
Kento Ohbayashi
YOYukiko Oyama
Yukiko Oyama
CYChiharu Yamaguchi
Chiharu Yamaguchi
TAToshiki Asano
Toshiki Asano
TYToshihiko Yada
Toshihiko Yada
YIYusaku Iwasaki
Yusaku Iwasaki
Diet-induced gastrointestinal distension is known to evoke satiation and suppress postprandial hyperglycemia; however, the underlying mechanisms remain poorly understood. This study explored how gastrointestinal distension regulates energy homeostasis by using inflating stomach formulation (ISF), the carbonated solution containing pectin that forms stable gel bubbles under acidic condition in the stomach. Here we show that, in mice, oral administration of ISF induced distension of stomach and proximal intestine temporarily, stimulated intestinal glucagon-like peptide-1 (GLP-1) secretion, and activated vagal afferents and brainstem. ISF suppressed food intake and improved glucose tolerance via enhancing insulin sensitivity. The anorexigenic effect was partially inhibited, and the beneficial glycemic effect was blunted by pharmacological GLP-1 receptor blockade and chemical denervation of capsaicin-sensitive sensory nerves. In HFD-fed obese mice showing arrhythmic feeding and obesity, subchronic ISF treatment at the light period (LP) onset for 10 days attenuated LP hyperphagia and visceral fat accumulation. These results demonstrate that gastrointestinal distension by ISF stimulates GLP-1 secretion and the vagal afferent signaling to the brain, thereby regulating feeding behavior and glucose tolerance. Furthermore, subchronic ISF treatment ameliorates HFD-induced visceral obesity. We propose the diet that induces gastrointestinal distension as a novel treatment of hyperphagic obesity and diabetes.

20 May 2025 in Diabetology International
Verified
Journal Article
Open access
PDF file
YMYuta Masuda
Yuta Masuda
KOKento Ohbayashi
Kento Ohbayashi
YIYusaku Iwasaki
Yusaku Iwasaki
Obesity continues to increase worldwide. The primary cause of obesity is overeating, but the development of pharmacological treatments for obesity related to overeating has taken longer than expected. Recently, agonists of glucagon-like peptide-1 (GLP-1) receptor, designed based on the gut hormone GLP-1, have been developed as anti-obesity drugs and have demonstrated remarkable efficacy in treating both obesity and diabetes. Meanwhile, recent research using factors that promote GLP-1 secretion has highlighted the significance of endogenous GLP-1 function. This review provides an overview of the anorexigenic effects, adverse effects, and their underlying mechanisms of GLP-1 receptor agonists and endogenous gut-derived GLP-1. Furthermore, it discusses the potential anti-obesity effects of dual agonists targeting both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor, which have gained attention in recent years. Finally, we compare the beneficial effects of GLP-1 receptor agonists and meal-induced gut GLP-1 secretion on overeating-induced obesity and discuss how combining these approaches may complement each other’s limitations and serve as a promising long-term strategy for preventing and treating obesity.

14 July 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
KNKoki Nishida
Koki Nishida
SUShinji Ueno
Shinji Ueno
YSYusuke Seino
Yusuke Seino
SHShihomi Hidaka
Shihomi Hidaka
NMNaoya Murao
Naoya Murao
ASAtsushi Suzuki
Atsushi Suzuki
(1) Background: Proglucagon-derived peptides (PDGPs) including glucagon (Gcg), GLP-1, and GLP-2 regulate lipid metabolism in the liver, adipocytes, and intestine. However, the mechanism by which PGDPs participate in alterations in lipid metabolism induced by high-fat diet (HFD) feeding has not been elucidated. (2) Methods: Mice deficient in PGDP (GCGKO) and control mice were fed HFD for 7 days and analyzed, and differences in lipid metabolism in the liver, adipose tissue, and duodenum were investigated. (3) Results: GCGKO mice under HFD showed lower expression levels of the genes involved in free fatty acid (FFA) oxidation such as Hsl, Atgl, Cpt1a, Acox1 (p < 0.05), and Pparα (p = 0.05) mRNA in the liver than in control mice, and both FFA and triglycerides content in liver and adipose tissue weight were lower in the GCGKO mice. On the other hand, phosphorylation of hormone-sensitive lipase (HSL) in white adipose tissue did not differ between the two groups. GCGKO mice under HFD exhibited lower expression levels of Pparα and Cd36 mRNA in the duodenum as well as increased fecal cholesterol contents compared to HFD-controls. (4) Conclusions: GCGKO mice fed HFD exhibit a lesser increase in hepatic FFA and triglyceride contents and adipose tissue weight, despite reduced β-oxidation in the liver, than in control mice. Thus, the absence of PGDP prevents dietary-induced fatty liver development due to decreased lipid uptake in the intestinal tract.